Filsuvez in Moderate-to-Severe Epidermolysis Bullosa Simplex

This pilot study will look at whether the topical Birch Triterpenes (Filsuvez) gel is safe and helpful for adults and children 6 months of age and older who have moderate to severe epidermolysis bullosa simplex (EBS). The study will examine whether the gel can reduce the number of blisters, help wounds heal faster, and improve comfort by reducing pain and itching and making daily activities easier.

NCT Number	NCT07756138
Lead Sponsor	Stanford University
Conditions	Epidermolysis Bullosa Simplex
Enrollment	10 participants
Start Date	2026-10
Primary Completion	2027-07-02 (estimated)
Study Completion	2028-06-18 (estimated)
Updated on ClinicalTrials.gov	2026-08-10